This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.

The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.

Janux Therapeutics and Bristol Myers Squibb (BMS) are developing a tumor-activated therapeutic in an exclusive licensing agreement.

While it is common to hear that drug developers are in the early stages of integrating artificial intelligence with their drug research, discovery, and development efforts, one Bristol Myers Squibb ...

This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.

[Editor’s note: The hacker requested that we remove the image for legal reasons, so it’s blurry now. We hope all’s well!] Lithium technology has ushered in a new era of batteries with exceptionally ...

Harald Hampel is recognized as an influential leader in neuroscience, and will bring expertise in Alzheimer's disease to BMS.

The battery market is heating up. In the United States, the Inflation Reduction Act has added to the growing momentum by offering electric-car tax credits as well as making billions of dollars ...

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.